Concepedia

Publication | Open Access

Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial

DOIFull Paper Access

118

Citations

21

References

2021

Year

Brendon L. Neuen, Megumi Oshima, Vlado Perkovic, Rajiv Agarwal, Clare Arnott, George L. Bakris, Christopher P. Cannon, David M. Charytan, Robert Edwards, José Luis Górriz,
European Heart Journal

Abstract

Among patients treated with renin-angiotensin-aldosterone system inhibitors, SGLT2 inhibition with canagliflozin may reduce the risk of hyperkalaemia in people with T2DM and CKD without increasing the risk of hypokalaemia.

References

YearCitations

Page 1